Melinta Therapeutics Inc.’s next-generation fluroquinolone delafloxacin now has another five years’ of marketing exclusivity, as one of the first drugs to receive a qualified infectious disease product designation under the Generating Antibiotic Incentives Now provisions recently passed by Congress.
Patents covering composition of matter of the Phase III-ready delafloxacin expire in 2016, including additional patent term adjustments or patent...